Portola's Hitting All-Time Highs: Here's Why the Stock Should Go Higher
Portola Pharmaceuticals' (NASDAQ: PTLA) won FDA approval of their first commercial drug, Bevyxxa in June, and that sent shares skyrocketing. Yet the market opportunity for Bevyxxa could total in the billions of dollars annually, and the potential approval of a second drug later this year suggests to me that shares could be heading even higher.
Bevyxxa is a factor Xa anticoagulant that can be used to prevent venous thromboembolism in acutely ill medical patients who are being discharged from hospitals following a serious medical event, such as heart failure, stroke, and infection.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
